首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
【24h】

Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.

机译:免疫抑制的基于总淋巴样照射的修复方案可使异基因造血干细胞移植治疗的患者出现移植排斥或移植失败后进行移植。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: To retrospectively evaluate the efficacy of total lymphoid irradiation (TLI)-based reconditioning regimens in patients with graft failure or graft rejection after allogeneic hematopoietic stem cell transplantation. METHODS AND MATERIALS: The results of 14 patients (7 adults and 7 children) with a variety of hematologic malignant diseases treated with a TLI-based reconditioning regimen with 7-Gy single-dose application plus anti-T-lymphocyte antibody OKT3 (n = 11) and/or antithymocyte globulin (n = 7)/fludarabine (n = 9), followed by an infusion of peripheral blood stem cells (n = 13) or bone marrow stem cells (n = 1) from related or unrelated donors, were retrospectively analyzed. RESULTS: Of the 14 recipients, the data from 11 were evaluable for engraftment after TLI-based reconditioning because 3 adults died early (at Day 2, 5, and 15) after the second transplantation of infectious complications. Engraftment in 4 adults was seen after a median of 12 days (range, 10-18) and occurred after a median of 10 days (range, 9-32) in the 7 children. TLI-based reconditioning was well-tolerated with no severe toxicity. The median overall survival and disease-free survival for the whole cohort was 140 days (range, 5-1,268). After a median follow-up of 681 days, the disease-free survival and overall survival rate was 85.7% and 85.7%, respectively, in the children. Despite engraftment in the 4 remaining adults, 1 died of fatal graft-vs.-host disease, 1 of infectious complications, 1 of disease relapse, and 1 of acute respiratory distress syndrome. CONCLUSIONS: In patients with graft failure or graft rejection after allogeneic hematopoietic stem cell transplantation, TLI-based reconditioning regimens allow sustained engraftment, paralleled by a favorable toxicity profile, potentially leading to long-term survival.
机译:目的:回顾性评估基于全淋巴细胞照射(TLI)的修复方案在异基因造血干细胞移植后移植失败或移植排斥的患者中的疗效。方法和材料:14例患有多种血液系统恶性疾病的患者(7例成人和7例儿童)采用基于TLI的修复方案联合7-Gy单剂量应用和抗T淋巴细胞抗体OKT3治疗的结果(n = 11)和/或抗胸腺细胞球蛋白(n = 7)/氟达拉滨(n = 9),然后从相关或无关的供体中注入外周血干细胞(n = 13)或骨髓干细胞(n = 1),进行回顾性分析。结果:在14位接受者中,来自11位患者的数据可在基于TLI的修复后进行移植评估,因为3位成年人在第二次感染并发症移植后较早死亡(在第2、5和15天)。在7位患儿中位数为12天(范围为10-18)之后,有4位成年人发生了移入,而在位数为10天(范围为9-32)之间发生了移植。基于TLI的修复具有良好的耐受性,且无严重毒性。整个队列的中位总生存期和无病生存期为140天(范围为5-1268)。在中位随访681天后,儿童的无病生存率和总生存率分别为85.7%和85.7%。尽管在其余4位成年人中有移植,但1例死于致命的移植物抗宿主病,1例感染并发症,1例疾病复发,1例急性呼吸窘迫综合征。结论:在异基因造血干细胞移植后出现移植失败或移植排斥的患者中,基于TLI的修复方案可实现持续植入,同时具有良好的毒性特征,有可能导致长期存活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号